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Abstract 
 
Objective: To preliminary investigate the link between the darkness hormone melatonin (MLT) and 
the pro-hypnotic effectiveness of the atypical antidepressant Trazodone (TRZ) in a group of mood dis-
order patients suffering of insomnia.  
Design and Methods: The study’s design comprised: i) the enrolment of insomniac outpatients, ii) 
baseline (t0) psychiatric and biochemical examinations; iii) the subsequent patients’ introduction into a 
treatment with TRZ for 3-4 weeks, followed by post-therapy re-evaluations (t1). The MLT function 
was investigated by t0/t1 ELISA determinations of 6-hydroxy-MLT sulfate (6-OH-MLTs) levels in ear-
ly-morning urines and HPLC analysis of morning MLT serum amount. Concomitantly, TRZ and its 
metabolite m-chloro-phenylpiperazine (m-CPP) were measured by HPLC in serum to monitor patients’ 
compliance/metabolism. 
Results: Seventeen insomniac outpatients, displaying mild symptoms of depression/anxiety resistant to 
antidepressants, completed TRZ therapy (dose:10-20 mg/day, bedtime). Serum TRZ levels (127± 57 
ng  ml-1, mean ± SD) confirmed patients’ compliance, while the anxiogenic metabolite m-CPP result-
ing almost undetectable. Moreover, the 6-OH-MLTs output was found increased at t1 vs. baseline val-
ues (t1: 58.4 ± 45.02 ng ml-1; t0: 28.6 ± 15.8 ng ml-1; mean ±SD, P < .05) in 9 patients who recovered 
both insomnia and depression/anxiety (P < .01). Unresponsive subjects showed instead no post-therapy 
6-OH-MLTs variation (t1: 48.53 ± 50.70 ng ml-1; t0 : 49.80 ± 66.53 ng ml-1). Morning MLT in serum 
slightly diminished at t1 without reaching the statistical significance, not allowing therefore to define 
the patients’ outcome.  
Conclusions: This initial investigation encourages to explore MLT networks as possible correlates of 
TRZ pro-hypnotic responses.  
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1.Introduction 
The disruption of the sleep-arousal cycle negatively affects the individual quality of life, provoking 
nocturnal awakenings and/or excessive sleepiness during the day [1]. Since decades, sleep disturbances 
have been found tightly interlaced to neuropsychiatric disorders: more than 80% of depressed people 
experience at least one sleep symptom [2]. Among these, insomnia is particularly difficult to manage 
by psychiatrists, especially as concerns its diagnosis and suitable treatment. Blurred boundaries in fact 
exist between primary insomnia and that secondary to psychiatry diseases: if insomnia can be the core 
of the clinical symptoms of a mood-anxiety disorder, it can also be the almost unique prodromal symp-
tom in an emerging psychiatric disease [3]; at the same time, a sleep dysfunction can be the residual 
sign in depressed patients after their remission, exposing them to a higher risk of relapse [4]. Sleep 
symptoms secondary to mood-anxiety diseases may be sub-threshold but invalidating in the long-term, 
while being often undiagnosed. Low-quality sleep and its persistence can significantly worsen the 
prognosis of patients with a major mood disorder [5], even increasing suicidality [6]. Another main as-
pect in the care of insomnia and depression is the possible arise of sleep side-effects during a therapy 
with antidepressants (ADs) owing to the psycho-stimulant effect of these compounds [7]. Therefore, 
such a varied portrayal suggests the need of adapted drugs/treatments. Beside GABAergic compounds, 
alternative pro-hypnotic drugs have been (re)discovered among the well-tolerated multifunctional ADs 
[8]. In particular, the “old” compound Trazodone (TRZ) [9,10], an atypical AD which behaves overall 
as a high-affinity antagonist of serotonin2A/2C (5-HT2A/2C) receptors and as a lower affinity inhibitor of 
5-HT reuptake (SARI), has shown a good pro-hypnotic efficacy in psychiatric patients. The action of 
TRZ on sleep is in fact attained at lower dosages than those provoking its antidepressant effect, pre-
sumably due to a combined anti-arousal effect resulting from its antagonism on both 5-HT2A/2C recep-
tors [11] and α-adrenergic and/or H-histaminergic receptor subtypes [12]. Nevertheless, the precise 
mechanism of action which underlies this TRZ specific effect has never been fully elucidated yet. In-
terestingly, some authors have reported that the acute administration of TRZ, 50 mg at bedtime, raises 
the nighttime pineal melatonin (MLT) release in healthy volunteers [13]. This is an important remark, 
since the pineal gland function is attracting ever increasing attention in clinical psychiatry because of 
the recognized reciprocal influence of mood and sleep neurocircuitries [14-16]. The substantiation of a 
main role of MLT system in the sleep-promoting action of TRZ would in fact open up towards, on the 
one hand, a deeper knowledge of the physiopathology of insomnia and MLT release, while, on the oth-
er, towards the delineation of more targeted uses of this drug in the clinical practice.  
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The present work aimed therefore at preliminary assessing if TRZ effectiveness on sleep could be sus-
tained by an action on MLT system in mood disorder patients suffering of insomnia. For this purpose, 
patients were enrolled and examined through suitable psychiatric rating scales before (baseline time, 
t0) and after a therapy (post-therapy time, t1) with TRZ, in concomitance to investigations on their mel-
atonergic function. The MLT parameters measured in patients were: the amounts of 6-hydroxy-
melatonin sulfate (6-OH-MLTs) in early-morning urines, a metabolic index strongly correlated to 
nighttime pineal MLT secretion [17, 18], and morning MLT in serum [19]. The patients’ compliance 
and TRZ metabolism were instead monitored through the determination of serum levels of TRZ and its 
anxiogenic metabolite m-chloro-phenylpiperazine (m-CPP) at t1.  
5 
 
 
2. Experimental 
2.1 Mood Disorder Patients  
2.1.1 First recruitment interview 
Mood disorder patients were enrolled at the Psychiatry Ambulatory Care of the Department of Clinical 
and Experimental Medicine of the University of Pisa, during their therapeutic follow-up. Recruitment 
occurred during the years 2012 and 2013 (winter and spring-time), within a total period of about 6 
months, through an initial interview carried out accordingly to established inclusion/exclusion criteria. 
Inclusion criteria were: age ≥ 18 years; a diagnosis of major mood disorder obtained by the Structural 
Clinical Interview (SCID) for the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-
TR) [20]; the presence of sleep disturbances at the time of the interview assessed by a “yes/no” test; 
the reading, endorsement and signature of the project previously approved by the Ethical Committee of 
the University of Pisa, in conformity to the World Medical Association Declaration of Helsinki. Exclu-
sion criteria were: a normal sleep assessed by a “yes/no” test, co-morbidity with a neurological or neu-
rodegenerative disease, the presence of renal and metabolic illnesses, alcohol/drug abuse, severe rheu-
matic/autoimmune disorders, pregnancy; a previous treatment with TRZ since at least 3 months. 
2.1.2 Sleep and psychiatric rating scales 
Each patient selected by the first interview underwent, within few days, programmed baseline (t0) 
blood/urine tests and psychiatric examinations. The severity of symptoms was appraised by skilled 
psychiatrists working at the Psychiatry Unit of the University of Pisa through specific and validated 
rating scales: 1) the «Insomnia Severity Index» scale (ISI) [21]; 2) the 17-items «Hamilton Rating 
Scale for Depression» (HAMD-17) [22]; 2) the State-Trait Anxiety Inventory  Form Y (STAI-Y1 and 
STAI-Y2) [23]. 
If deemed eligible on the basis of t0 scores obtained by these 4 clinical evaluation scales and respective 
cut-off values [21-23], patients were definitely admitted to the survey. Thus, they were introduced into 
a period of 3-4 weeks under TRZ therapy and evaluated again by these same questionnaires at the end 
of the treatment (t1) to complete the study. The treatment timing was established by considering the 
minimum time necessary to observe a possible patients’ response on both sleep and mood-anxiety to-
nus. To avoid a seasonal influence on the study’s results, t0 and t1 clinical/biochemical investigations 
were carried out on each patient by respecting photoperiod. 
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2.1.3 Drug treatment  
Daily dosages of TRZ, taken at bedtime (10.00 - 11.30 pm), were set up in respect of patient’s diagno-
sis, pharmacological treatment and clinical state examined at t0. The established TRZ dosage was kept 
constant for the study’s duration. Patients were allowed to maintain t0 treatment with other psychoac-
tive agents, provided that every change of drug and/or daily dosages was an exit criterion from the 
study. Patients taking benzodiazepines (BDZs) at doses not exceeding 1 mg/day and showing compa-
rable clinical symptoms/scores to those who were not taking these compounds were also admitted to 
the investigation. The communication to the medical staff of arising illnesses or significant adverse ef-
fects during TRZ treatment also resulted in the exclusion from the study. 
 
2.2 Biochemical investigations 
2.2.1. Collection of biological samples 
The day of the first interview, each patient had received an urine collection container and suitable 
guidelines to gather first-morning urines for the measurement of nighttime 6-OH-MLTs excretion. 
Briefly, patients were asked to collect first morning urines (07.00-08.30 am) at home when fasting, a 
procedure to be done the same day of the beginning of the study (t0). Patients were also asked to un-
dergo a t0 peripheral venous blood withdraw of about 7 ml carried out between 08.15 and 09.30 am at 
the Psychiatry ward of the Department, before the clinical assessments. This same procedure was re-
peated at t1. After urine and blood delivery, samples were immediately transported to the laboratory of 
the Department of Pharmacy, University of Pisa, in apposite bags for the transport of biological fluids. 
At the laboratory, urines were measured for clinical-chemistry parameters by means of an automated 
analyzer of reactive chemical strips (Aution-Micro, Menarini, Italy) and centrifuged at 2,000 g for 10 
min at RT. Ensuing supernatants were taken and stored at -20°C until 6-OH-MLTs assay. Additional-
ly, venous blood, collected into a serum-test tube provided at the Psychiatry ward, was left to clot and 
centrifuged at 2,600 g for 15-20 min, RT. Serum supernatants were then divided into aliquots directly 
processed for routine analyses and the measure of MLT, TRZ and m-CPP or stored at -80°C.  
2.2.2 Urinary 6-OH-MLTs assay 
The excretion of the sulfate hydroxyl metabolite of MLT in urines collected at t0 and t1 was evaluated 
by means of a competitive 96-wells plate solid-phase enzyme immunoassay (ELISA) kit (IBL Interna-
tional, GMBH, Germany). The day of the assay, urine samples were thawed, allowed to reach RT, di-
luted as indicated and directly added to plates for the determination of 6-OH-MLTs; after incuba-
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tion/washing steps, samples were measured by a Wallac Victor2 multilabel/multitask 96-wells plate 
reader (PerkinElmer, USA) preset at 450 nm. Concentrations of urinary 6-OH-MLTs were then inter-
polated from the calibration curve equation and presented as ng ml-1 urine volume, standardized for 
urine concentration/dilution by the specific gravity correction [24]. 
2.2.3 Determination of MLT levels in serum 
Morning circulating MLT was estimated in patients’ serum extracted by dichloromethane, in accord to 
a previously described procedure [25]. The pineal hormone was then measured in all 17 patients at t0 
and t1 by HPLC: the isocratic chromatography was achieved at a flow rate of 0.8 ml min-1  and RT, us-
ing an UltiMate™ 3000 HPLC system (Thermofisher Scientific,USA). The mobile phase was com-
posed by 0.1M NaH2PO4, 4mM Sodium DecanSulfonate, 0.1mM Na2-EDTA in 25% methanol (75:25, 
v:v), pH 5. All chemicals employed were of the best analytical HPLC grade (Romil, Cambridge, UK; 
Sigma-Aldrich, USA; Applichem, Germany).The stationary phase was a C18 Atlantis-T3 analytical 
column (3 µm beads, 4.5 x 150 mm), in-line with a C18 Atlantis T3 pre-column, both purchased from 
Waters Spa (USA). Injection volume was 100 µl using a Reodyne injection valve. Elution peaks were 
visualized through a double detection device, employing in-line electrochemical (Coulochem III, Esa, 
Thermofisher Scientific,USA) and fluorimetric (UltiMate™ FLD-3000, Thermofisher Scientific,USA) 
detectors. Electrochemical detection was carried out by means of a guard electrode (ECD1) preset at 
+100 mV and a second, analytical palladium electrode (ECD2) set at +550 mV. Fluorimetric analysis 
was performed at the λex = 280 nm and the λem = 345 nm. Under present chromatographic conditions, 
the MLT standard (> 99%) eluted at a retention time of about 20-21 min, permitting to identi-
fy/quantify MLT in unknowns. The HPLC measure of serum MLT was validated using a highly sensi-
tive ELISA kit (IBL International, GMBH, Germany) in 8 of the 17 subjects, both at t0 and t1. This kit 
is based upon a solid-phase immunoenzyme competitive principle employing biotin-labeled MLT, 
specific antisera, and streptavidin-conjugated phosphatase alkaline. Plates were read at 405 nm by the 
Wallac Victor2 spectrophotometer. 
2.2.4 Trazodone and m-CPP assay in serum 
Trazodone and its main metabolite m-CPP were quantified in t1 sera by HP-LC. Trazodone and m-CPP 
were extracted by a liquid:liquid partition procedure under alkaline conditions, using n-hexane as the 
organic solvent and buspirone as the internal standard, following a slightly modified method from Pa-
tel et al [26]. After extraction, TRZ and m-CPP were analyzed by reversed-phase HP-LC and UV-
photodiode (DAD) detection working at dual and variable wavelength [27].  
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2.3 Statistical analyses 
Data are presented as the mean ± standard deviation (SD) and ranges (min and max values). Non-
parametric inferential analyses were employed for both clinical and biochemical comparisons. Before 
(t0)-and-after-(t1) tests or unpaired data comparisons were carried out by the Wilcoxon and the Mann-
Whitney tests, respectively; for correlations, the Spearman method was applied. The statistical thresh-
old was always set at P = 0.05. For descriptive and inferential statistics, correlation/regression analyses 
or to calculate analytes’ calibration curves/lines, the Graph-Pad Prism software was used (Graph-Pad 
Prism, version 5, San Diego, CA,USA).  
Clinical scores appraised by the ISI, HAMD and STAI-Y questionnaires were normalized as the per-
cent (%) reduction observed at t1 vs. the t0 value, considered the 100%; values greater at t1 than t0 were 
taken as a 0% reduction of symptoms. 
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3.Results 
3.1 Clinical evaluations 
Twenty-five outpatients were selected through the first interview. Non-eligibility at baseline by clini-
cians, follow-up discontinuity, inadequate information or protocol adherence, and therapy drop-out 
during treatment, resulted in the completion of the study until t1 by 17 patients. Table 1 reports the 
baseline characteristics of these patients: overall, they were overweight middle-age women, presenting 
mild insomnia accompanied by mild-to-moderate depressive symptoms resistant to a therapy with 
ADs. Most of them had initial or central insomnia. Only two patients were insomniac in the last part of 
the night. Most patients also displayed acute and/or chronic anxiety symptoms defined by significantly 
higher scores for chronic/trait anxiety (STAI-Y2) (Table 2, Mann-Whitney test). Seven subjects pre-
sented also a clinical history of panic attacks. At the time of their recruitment, all patients were receiv-
ing ADs and/or other psychoactive agents since at least 2 months: i) non-bipolar depressed patients 
were taking one or two Selective-Serotonin Reuptake Inhibitors (SSRIs), except fluvoxamine, at doses 
comprised between 5 and 75 mg/day; ii) bipolar depressed patients were instead taking one SSRI, ex-
cept fluvoxamine, (dose range: 5-150 mg/day) associated to a mood stabilizer among carbamazepine 
or lamotrigine (150-200 mg/day), lithium or valproate (450-900 mg/day) and/or one or two antipsy-
chotic drugs among perfenazine and aripiprazole (4-8 mg/day) or quetiapine (300 mg/day). Seven of 
them were constantly taking BDZ within allowed dosage ranges. 
The applied therapeutic protocol used a very low TRZ dosage, 10-20 mg/day, taken at bedtime, as pre-
viously indicated.  
Table 2 reports results concerning comparisons between clinical scores obtained at t1 vs. t0 ones. The 
ISI, HAMD and trait-anxiety (chronic) STAI-Y2 scores were found significantly reduced at t1 vs. t0, 
while the state-anxiety (acute) STAI-Y1 scale only showed a tendency to decrease. Afterward, due to 
the purpose of this study, we divided patients into responders or non-responders, based on post-therapy 
ISI scores and ISI % reduction, considering the sleep response as hierarchical. Nine patients recovered 
insomnia very well: 8 lowered their ISI scores from sub-threshold/moderate (8 ≤ ISI ≤ 21) to clinically 
irrelevant (ISI ≤ 7) at t1 [21]; 1 patient showing an ISI reduction of about -40%, thus decreasing insom-
nia from moderate to sub-threshold [21], was also considered responder to TRZ treatment. Conversely, 
the remaining patients (n=8) were found un- or scarcely-responsive to low-dose TRZ displaying persis-
tent sleep symptoms, in accord to ISI guidelines (ISIt1 ≥ 8) [21]. Five of them even reported increased 
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t1 ISI scores vs. t0. This diverse sleep response was not conceivably due to a difference in TRZ dosag-
es, since patients’ daily doses did not significantly differ between subjects who responded to therapy 
(12.8 ± 4.4 mg) and those who did not (11.2 ± 2.3 mg) (Mann-Whitney, P > 0.05). The same result 
was found for TRZ dose normalized for body weight (given dose): 0.161 ± 0.067 mg kg-1 in responders 
vs.  0.122 ±  0.049 mg Kg-1 in non-responders (P >0.05). As well, BDZ administration did not seem to 
affect TRZ effectiveness, since among the 8 non-responders 4 were taking BDZ during the study while 
the other 4 did not. 
Figure 1(a) depicts ISI-score before-and-after comparisons separately conducted in sleep responders 
and non-responders. Figure 1(b-d) shows that sleep responders were also found to significantly im-
prove HAM-D and STAI-Y2 ratings.  From Figure 1, the % reduction of clinical scores in responders 
was: (a) ISI, 68 ± 24 % (36-100%); (b) HAMD-17, 51 ± 20% (33-91%); (c) STAI-Y1, 11 ± 8 % (0-
20); (d) STAY-Y2, 16 ± 14 % (0-36%);   in non-responders, it resulted instead: (a) ISI, 10 ± 13% (0-
25%) ; (b) HAMD-17, 20 ± 24% (0-62.5%); (c) STAI-Y1, 11 ± 11 % (0-30%); (d) STAY-Y2, 8 ± 11% 
(0-29.5%). Furthermore, diagnosis and smoking behavior would exert an impact on clinical response: 
depression and non-smoking habit were prevalent in responsive subjects (n=7 depressed vs. n=2 bipo-
lar subjects; n=7 non-smokers vs. n=2 smokers), while more smoker bipolar individuals were found 
among non-responders (n=5 bipolar vs. n=3 depressed subjects; n=6 smokers vs. n=2 non-smokers). 
Sleep responders and non-responders had similar t0 scores, confirming the comparable insom-
nia/depression severity at baseline (data not shown, Mann-Whitney, P > 0.05).   
 
3.2 Biochemical assessments 
Routine analyses of t0 and t1 serum/urines reported standard check up clinical-chemistry parameters 
within the normal range, indicating that all patients were in good health at the time of the study. Urine 
specific gravity was always comprised between the Spotchem healthy range, 1.005 to 1.030, validating 
urine samples for further investigation.  
Trazodone was detected in all 17 serum samples collected at t1: the drug serum levels accounted for by 
127 ± 57 ng ml-1, demonstrating the good compliance to treatment. Under our experimental conditions, 
other drugs used in combination with TRZ did not interfere during HPLC analyses [27]. As shown in 
Figure 2(a), TRZ levels in ISI responders, 130 ± 66 ng ml-1, were found comparable to those measured 
in non-responders, 116 ± 47 ng ml-1 (P > 0.05), accordingly to respective drug daily dosages. The main 
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metabolite of TRZ, the psycho-stimulant and anxiogenic compound m-CPP, was found almost unde-
tectable in serum, as expected from the administered low dosages of the parent drug. The metabolite 
was detected in 3 subjects only where it accounted for by 22 ng ml-1, on average. These 3 patients were 
all found responsive to the TRZ therapy. Figure 2(b) shows instead the positive trend of serum TRZ 
levels in respect to ISI % reduction (sleep response), when the analysis was performed in responder pa-
tients only. 
When comparing urinary 6-OH-MLTs levels in the 17 patients altogether, these increased from t0: 
39.1± 46.6 ng ml-1, to t1: 53.6 ± 46.5 ng ml-1, without reaching the statistical significance (Wilcoxon, P 
> 0.05). Figure 3(a,b) shows t0/t1 comparisons between 6-OH-MLTs levels separately carried out in re-
sponders and non-responders: metabolite excretion increased more than 60% on average at t1 vs. t0 in 8 
of the 9 responders, resulting in a significant variation (P < 0.05), Figure 3(a). In contrast, t0/t1 urinary 
6-OH-MLTs levels were found almost similar or decreased in patients unresponsive to TRZ, failing to 
reach the statistical threshold (P > 0.05), Figure 3(b). 
As concerns MLT concentration in morning serum, this was reduced at t1, albeit not significantly, in all 
patients: it measured 59.7 ± 43.2 pg ml-1 at t0 vs. 51.8 ± 47.7 pg ml-1 at t1,  (P > 0.05). In Figure 3(c,d) 
are shown separate comparisons between serum MLT in responders vs. non-responders: in spite that 
the post- therapy values tended to be reduced in both groups, the statistical significance was not 
reached (P > 0.05). 
All t0 MLT-ergic parameters in responders were not different from non-responders (Mann-Whitney, P 
> 0.05). Diagnosis had no significant impact on MLT biochemistry, except a tendency towards lower 
serum or urine levels of MLT parameters in bipolar depressed patients (data not shown, Mann-
Whitney, P = 0.09).  On the whole, a high data dispersion was obtained by both ELISA and HP-LC 
techniques. 
The comparison between serum levels of MLT obtained by HP-LC and those attained by ELISA, re-
vealed a strong correspondence of these two methodologies: Spearman coefficient of correlations at t0 
and t1 were, r=0.94 (P= 0.0006) and r=0.92 (P= 0.0012), respectively. 
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4.Discussion 
To our knowledge, this pilot study addresses a topic which has not been investigated before, the in-
volvement of MLT system in the low-dose efficacy of the atypical AD TRZ on insomnia in patients 
with mood disorders. At first, the study’s design allowed to recruit patients displaying mild depres-
sion/anxiety symptoms resistant to AD therapies accompanied by insomnia. Then, we could observe  
that doses as low as 10-20 mg/day of TRZ were able to improve sleep and mood/anxiety symptoms in 
more than half of participants (≈ 53%). Since the antidepressant effect of TRZ is usually attained at 
dosages comprised between 150-500 mg/day [12], our results report a potential for TRZ at rebalanc-
ing/enhancing SSRIs’ efficacy [7] through a synergic action on both sleep and mood. Other authors 
have instead reported a dissociation between insomnia and depression remission after TRZ administra-
tion at a much higher drug dosage, 100 mg/day [28]. Such divergences could be ascribed to the dis-
crepant study’s design, patients’ selection or degree of symptoms’ severity as well as to the different 
therapeutic protocols applied, without wash-out procedures in our work. Interestingly, responders had 
a prevalent diagnosis of atypical depression while, after the same therapy, a trend for bipolar patients 
amongst non-responders was observed. The good response to TRZ reported in patients with atypical 
depression might reflect the peculiar clinical features of this form such as the presence of symptoms 
overlapping seasonal-affective disorders [29]. Also smoking behavior seems to have an impact on clin-
ical response, suggesting that bipolar and smoker individuals could represent a distinct cohort of pa-
tients. It is noteworthy to consider that the reduction of state-anxiety after the low-dose TRZ treatment 
was weaker than that reported for chronic, generalized anxiety, a finding which could also explain the 
incomplete remission of patients. Clinical improvement was supported by results obtained for TRZ se-
rum levels, revealing the good compliance of all patients to the drug. Trazodone serum levels were, on 
average, quite proportional when compared to those reported in the current literature in patients taking 
higher dosages [30]. The main TRZ metabolite, m-CPP, was almost undetectable in our patients, re-
sulting under the method’s limit of quantification [27]. In fact, plasma/serum m-CPP is about the 1-
10% of TRZ [31]. The 3 patients in whom serum m-CPP was quantified were also found to respond 
well to TRZ, suggesting that, at the maximal concentration determined herein, this metabolite cannot 
counteract the sedative effects of its parent compound [32]. Results on TRZ serum levels were congru-
ent with a pharmacological action [12], concurrently discouraging the exclusive effect of placebo on 
patients’ clinical responses and providing support to the reported biochemical results on MLT func-
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tion. The main finding of this work consists in fact in the significantly increased excretion of the me-
tabolite 6-OH-MLTs measured in first morning urine of responder patients only, reflecting an en-
hanced nighttime production of the pineal hormone in these subjects and suggesting an interaction be-
tween TRZ and MLT system, as previously observed by Morera and co-authors [13]. Our basal urinary 
6-OH-MLTs levels were, on average, about 1.5-2 folds lower than those measured in healthy Italian 
volunteers [33] as well as in non depressed controls from other countries [18,34]. Conversely, morning 
levels of MLT in serum reported in our study were 1.5-2 folds higher, on average, than those measured 
in healthy subjects by others: using the ELISA method, Keskin et al. [35] showed a mean circulating 
morning MLT values of about 30 pg ml-1 in control, non-depressed subjects. Khaleghipour et al. [36] 
showed much lower MLT serum levels at 8.00 a.m. in healthy subjects (about 10 pg ml-1), still accom-
panied by a 2-fold higher MLT in non-medicated depressed patients. Beside, Khaleghipour and coau-
thors reported lower nighttime MLT serum levels in subjects with depression [36]. Thus, theirs and our 
results would imply a blunted MLT release during the night with elevated MLT levels in the morning, 
probably due to a delayed nighttime peak of the pineal hormone. A similar pattern of MLT release has 
been already found in depressed subjects, even if not unanimously replicated [37]. Morning MLT 
showed only a tendency to reduction after TRZ therapy in our patients, probably due to a prevailing 
action of the drug on nighttime MLT release [13]. The negative result obtained for morning MLT se-
rum levels could also derive from the inherent limitation of a single blood sample in the day light-
phase, at low pineal activity, in removing interferences linked to the well-known high inter-individual 
variability of the MLT circadian metabolic profile, influenced by genetics, life-style and environmental 
factors, in addition to the concomitant treatment with SSRIs or other drugs [38,39]. Indeed, as early-
morning 6-OH-MLTs reflects the sum of nighttime pineal secretion, this parameter would be a more 
robust indicator of the drug’s action, at its low doses, on MLT system. A main issue as concerns uri-
nary 6-OH-MLTs for appraising pineal function resides in the fact that this represents an indirect and 
cumulative measure of MLT production, being the product of II pass sulfoconjugation enzymes; by 
contrast, for logistic and ethical problems, urine collection is surely a non-invasive and inexpensive 
procedure [15].  
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5. Conclusions 
To sum up, our pilot examination, considering its intrinsic limitations, would support the role of circa-
dian MLT as a biological indicator of pro-hypnotic/antidepressant benefits of TRZ and encourages to 
pursue the study.  If confirmed, present findings would contribute to better define the molecular effec-
tors of MLT on sleep and mood tonus [40], being also helpful to pharmacologists and clinicians. 
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Figure legends 
Figure 1 – Scores on psychiatric rating scales in sleep responders and non-responders. Respond-
ers showed: (a) ISI,  t0 = 12.2 ± 2.6; t1= 3.45 ± 2.9; (b)  HAMD-17, t0 = 17.4 ± 5.1; t1: 8.8 ± 4.7; (c) 
STAI-Y1, t0: 45.11 ± 12.45; t1: 40.56 ± 10.44; (d) STAI-Y2,  t0 = 58.0 ± 9.0; t1: 48.0 ± 10.0. Non-
responders displayed: (a) ISI, t0: 13.0 ± 4.0; t1: 13.0 ± 3.6; (b)  HAMD-17, t0: 17.0 ± 2.0; t1: 13.2 ± 5.0; 
(c) STAI-Y1, t0: 44.5 ± 10.0; t1: 42.0 ± 6.1; (d) STAI-Y2, t0: 48.0 ± 8.1; t1: 46.0 ± 5.1. Wilcoxon, (**), 
P< 0.01; (*), P < .05; (°) nearly significant, P< 0.10; (ns), P > 0.05. 
Figure 2- Serum levels of Trazodone. (a) TRZ levels in responders and non-responders, separately; (b) 
Spearman correlation between TRZ levels and ISI % reduction in responders. Mann-Whitney, (ns), not 
significant, P > 0.05; Spearman (*), P < 0.05. The line represents the trend of the relationship between 
variables, from the best fit of linear regression analysis of data. 
 
 
Figure 3- MLT parameters in responder and non-responder patients. Urinary 6-OH-MLTs in re-
sponders increased from, (a): t0, 29.60 ± 15.83 .to t1, 58.04 ± 45.02 ng ml-1; in non-responders it meas-
ured (b): t0, 49.8 ± 66.53 vs. t1 48.53± 50.68 ng ml-1. Serum MLT in responders was, (c): t0, 59.8 ± 42.5 
vs. t1, 52.3 ± 38.9 pg ml-1; in non-responders, (d): t0, 59.6 ± 46.9 vs. t1, 51.2 ± 58.8 pg ml-1. Wilcoxon, 
(*), P < 0.05; (ns), not significant, P > 0.05. 
 
 
